Phathom Historical Income Statement

PHAT Stock

USD 8.87 0.10 1.11%

Historical analysis of Phathom Pharmaceuticals income statement accounts such as Total Revenue of 716.1 K, Other Operating Expenses of 129.9 M, Research Development of 71.7 M or Total Operating Expenses of 129.9 M can show how well Phathom Pharmaceuticals performed in making a profits. Evaluating Phathom Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Phathom Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Phathom Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Phathom Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

About Phathom Income Statement Analysis

Phathom Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Phathom Pharmaceuticals shareholders. The income statement also shows Phathom investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Phathom Pharmaceuticals Income Statement Chart

At this time, Phathom Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 603.8 K in 2024, whereas Operating Income is likely to drop (175.7 M) in 2024.

Selling General Administrative Other Operating Expenses Operating Income Research Development Total Operating Expenses Reconciled Depreciation

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Phathom Pharmaceuticals. It is also known as Phathom Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Phathom Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Phathom Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Phathom Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Phathom Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.At this time, Phathom Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 603.8 K in 2024, whereas Operating Income is likely to drop (175.7 M) in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	521K	620K	575K	450.3K
Cost Of Revenue	521K	620K	167K	158.7K

Reconciled Depreciation Cost Of Revenue

Phathom Pharmaceuticals income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Reconciled Depreciation	Non Operating Income Net Other
Net Interest Income		-0.11	-1.0	-0.97	-0.8	0.84	0.74	0.83	-0.52	0.78	-0.8	0.74	0.25	0.79	-0.79	-0.34	-0.51	-0.85	0.86
Depreciation And Amortization	-0.11		0.1	0.16	-0.17	0.15	0.48	0.16	-0.45	0.31	-0.17	0.48	0.93	0.36	0.68	-0.02	0.18	0.2	-0.18
Interest Expense	-1.0	0.1		0.96	0.77	-0.83	-0.73	-0.81	0.51	-0.76	0.77	-0.73	-0.26	-0.78	0.79	0.41	0.45	0.81	-0.83
Selling General Administrative	-0.97	0.16	0.96		0.86	-0.9	-0.76	-0.89	0.6	-0.83	0.86	-0.76	-0.2	-0.83	0.79	0.19	0.66	0.93	-0.94
Other Operating Expenses	-0.8	-0.17	0.77	0.86		-0.99	-0.93	-0.99	0.89	-0.98	1.0	-0.93	-0.45	-0.97	0.44	-0.11	0.79	0.92	-0.83
Operating Income	0.84	0.15	-0.83	-0.9	-0.99		0.94	1.0	-0.89	0.99	-0.99	0.94	0.45	0.97	-0.49	0.02	-0.75	-0.92	0.84
Net Income From Continuing Ops	0.74	0.48	-0.73	-0.76	-0.93	0.94		0.94	-0.92	0.98	-0.93	1.0	0.73	0.99	-0.23	-0.04	-0.58	-0.74	0.7
Ebit	0.83	0.16	-0.81	-0.89	-0.99	1.0	0.94		-0.89	0.99	-0.99	0.94	0.45	0.97	-0.48	0.05	-0.77	-0.92	0.84
Research Development	-0.52	-0.45	0.51	0.6	0.89	-0.89	-0.92	-0.89		-0.93	0.89	-0.92	-0.63	-0.91	0.08	-0.19	0.65	0.68	-0.55
Ebitda	0.78	0.31	-0.76	-0.83	-0.98	0.99	0.98	0.99	-0.93		-0.98	0.98	0.59	1.0	-0.35	0.04	-0.71	-0.85	0.78
Total Operating Expenses	-0.8	-0.17	0.77	0.86	1.0	-0.99	-0.93	-0.99	0.89	-0.98		-0.93	-0.45	-0.97	0.44	-0.11	0.79	0.92	-0.83
Income Before Tax	0.74	0.48	-0.73	-0.76	-0.93	0.94	1.0	0.94	-0.92	0.98	-0.93		0.73	0.99	-0.23	-0.04	-0.58	-0.74	0.7
Total Other Income Expense Net	0.25	0.93	-0.26	-0.2	-0.45	0.45	0.73	0.45	-0.63	0.59	-0.45	0.73		0.64	0.38	-0.14	-0.02	-0.11	0.14
Net Income	0.79	0.36	-0.78	-0.83	-0.97	0.97	0.99	0.97	-0.91	1.0	-0.97	0.99	0.64		-0.33	0.01	-0.67	-0.82	0.77
Income Tax Expense	-0.79	0.68	0.79	0.79	0.44	-0.49	-0.23	-0.48	0.08	-0.35	0.44	-0.23	0.38	-0.33		0.33	0.4	0.7	-0.7
Gross Profit	-0.34	-0.02	0.41	0.19	-0.11	0.02	-0.04	0.05	-0.19	0.04	-0.11	-0.04	-0.14	0.01	0.33		-0.6	-0.13	0.03
Cost Of Revenue	-0.51	0.18	0.45	0.66	0.79	-0.75	-0.58	-0.77	0.65	-0.71	0.79	-0.58	-0.02	-0.67	0.4	-0.6		0.86	-0.78
Reconciled Depreciation	-0.85	0.2	0.81	0.93	0.92	-0.92	-0.74	-0.92	0.68	-0.85	0.92	-0.74	-0.11	-0.82	0.7	-0.13	0.86		-0.94
Non Operating Income Net Other	0.86	-0.18	-0.83	-0.94	-0.83	0.84	0.7	0.84	-0.55	0.78	-0.83	0.7	0.14	0.77	-0.7	0.03	-0.78	-0.94

Click cells to compare fundamentals

Phathom Pharmaceuticals Account Relationship Matchups

Phathom Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	(3.1M)	(3.5M)	(6.7M)	(25.2M)	(34.1M)	(32.4M)
Interest Income	1.1M	1.1M	41K	2.1M	7.9M	8.3M
Depreciation And Amortization	(48.5M)	300K	521K	620K	575K	603.8K
Interest Expense	4.2M	4.6M	6.8M	27.3M	42.0M	44.1M
Selling General Administrative	6.9M	27.5M	62.7M	101.0M	117.9M	123.8M
Other Operating Expenses	106.2M	125.7M	135.1M	172.4M	168.0M	129.9M
Operating Income	(106.2M)	(125.7M)	(135.1M)	(172.4M)	(167.3M)	(175.7M)
Net Income From Continuing Ops	(255.1M)	(129.1M)	(143.9M)	(197.7M)	(201.6M)	(211.7M)
Ebit	(106.2M)	(124.5M)	(135.1M)	(172.4M)	(159.6M)	(167.6M)
Research Development	99.3M	98.1M	72.3M	71.4M	49.9M	71.7M
Ebitda	(154.7M)	(124.2M)	(134.6M)	(171.8M)	(159.0M)	(167.0M)
Total Operating Expenses	106.2M	125.7M	135.1M	172.4M	167.8M	129.9M
Income Before Tax	(255.1M)	(129.1M)	(143.9M)	(197.7M)	(201.6M)	(211.7M)
Total Other Income Expense Net	(148.9M)	(3.4M)	(8.8M)	(25.3M)	(34.3M)	(36.0M)
Net Income Applicable To Common Shares	(255.1M)	(129.1M)	(143.9M)	(197.7M)	(178.0M)	(186.8M)
Net Income	(209.7M)	(133.3M)	(148.1M)	(223.0M)	(201.6M)	(211.7M)
Income Tax Expense	(45.4M)	4.3M	4.2M	25.3M	41.8M	43.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Phathom Historical Income Statement

About Phathom Income Statement Analysis

Phathom Pharmaceuticals Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Phathom Pharmaceuticals income statement Correlations

Phathom Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Phathom Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Phathom Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Ebitda
Ebitda	+ 0.99	Operating Income
Net Income	+ 0.99	Net Income From Continuing Ops

Interest Expense	- 1.0	Net Interest Income
Total Operating Expenses	- 0.99	Ebit
Total Operating Expenses	- 0.99	Operating Income
Ebit	- 0.99	Other Operating Expenses
Operating Income	- 0.99	Other Operating Expenses
Total Operating Expenses	- 0.98	Ebitda